Yarrow Bioscience

Yarrow Bioscience Cash Conversion

The Cash Conversion Rate (OCF/Net Income) of Yarrow Bioscience (YARW) as of Oct 25, 2026 is 125.08 %. In the previous year, Cash Conversion Rate (OCF/Net Income) was 85.28 % — a change of 46.66% (higher).

Cash Conversion

125.08 %

YoY

46.66%

Last updated:

Cash Conversion Rate (OCF/Net Income) of Yarrow Bioscience is 2025 125.08 % . Cash Conversion Rate (OCF/Net Income) of Yarrow Bioscience was 2024 85.28 % . It decreases by 46.66% higher compared to the previous year.

The Yarrow Bioscience Cash Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cash Conversion
Date
Cash Conversion
Jan 1, 2018
102.50 USD
Jan 1, 2019
92.39 USD
Jan 1, 2020
53.64 USD
Jan 1, 2021
76.87 USD
Jan 1, 2022
125.81 USD
Jan 1, 2023
89.07 USD
Jan 1, 2024
85.28 USD
Jan 1, 2025
125.08 USD
The Yarrow Bioscience Cash Conversion history
YEARCash ConversionYoY
125.08 %+46.66%
85.28 %-4.25%
89.07 %-29.20%
125.81 %+63.67%
76.87 %+43.31%
53.64 %-41.94%
92.39 %-9.87%
102.50 %+5.51%
97.15 %+496.55%
16.29 %-82.06%
90.78 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Yarrow Bioscience Stock analysis

What does Yarrow Bioscience do? Yarrow Bioscience Inc, based in New York, is a clinical-stage biotechnology company focused on developing transformative therapies for autoimmune thyroid diseases. Its lead candidate, YB-101, is a humanized monoclonal antibody targeting the thyroid-stimulating hormone receptor (TSHR) for treating Graves' disease and thyroid eye disease. Listed on 25 January 2018, the company operates with a team of 10 employees. Yarrow Bioscience is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Yarrow Bioscience stock

Cash Conversion Rate (OCF/Net Income) of Yarrow Bioscience is 125.08 % in 2025.

Cash Conversion Rate (OCF/Net Income) of Yarrow Bioscience changed from 85.28 % to 125.08 %, representing a 46.66% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Cash Conversion Rate (OCF/Net Income) Yarrow Bioscience since 2006 – with annual values, charts, and detailed analysis.

Cash conversion measures how effectively net income converts to operating cash flow. Ratios above 100% indicate high-quality, cash-backed earnings.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Conversion Rate (OCF/Net Income)'s Yarrow Bioscience with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Conversion Rate (OCF/Net Income)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Conversion Rate (OCF/Net Income).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Cash Flow — Yarrow Bioscience

Operating Cash FlowCapital ExpendituresFree Cash FlowFCF per ShareDividends PaidShare BuybacksInvesting Cash FlowFinancing Cash FlowCapEx / RevenueCash Flow per ShareStock-Based CompensationChange in Working CapitalAcquisitions (Net)Net Change in CashCapEx/OCFFCF/Net IncomeFCF ConversionCash ConversionTotal Shareholder PayoutCapEx/D&A

All Key Metrics — Yarrow Bioscience